JPH0460090B2 - - Google Patents
Info
- Publication number
- JPH0460090B2 JPH0460090B2 JP57234521A JP23452182A JPH0460090B2 JP H0460090 B2 JPH0460090 B2 JP H0460090B2 JP 57234521 A JP57234521 A JP 57234521A JP 23452182 A JP23452182 A JP 23452182A JP H0460090 B2 JPH0460090 B2 JP H0460090B2
- Authority
- JP
- Japan
- Prior art keywords
- long
- surfactant
- lipid
- drug
- acting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 claims description 36
- 229940079593 drug Drugs 0.000 claims description 31
- 238000002360 preparation method Methods 0.000 claims description 27
- 150000002632 lipids Chemical class 0.000 claims description 22
- 239000004094 surface-active agent Substances 0.000 claims description 14
- -1 sucrose fatty acid ester Chemical class 0.000 claims description 10
- 238000002844 melting Methods 0.000 claims description 9
- 230000008018 melting Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 238000013268 sustained release Methods 0.000 claims description 7
- 239000012730 sustained-release form Substances 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 230000005923 long-lasting effect Effects 0.000 claims description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003405 delayed action preparation Substances 0.000 claims description 4
- 239000012188 paraffin wax Substances 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims 2
- 238000010828 elution Methods 0.000 description 20
- 238000000034 method Methods 0.000 description 14
- 238000004090 dissolution Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 229920001688 coating polymer Polymers 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 238000007909 melt granulation Methods 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- TVVTWOGRPVJKDJ-UHFFFAOYSA-N Befunolol hydrochloride Chemical compound [Cl-].CC(C)[NH2+]CC(O)COC1=CC=CC2=C1OC(C(C)=O)=C2 TVVTWOGRPVJKDJ-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960004374 befunolol Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229960000330 bupranolol Drugs 0.000 description 1
- HQIRNZOQPUAHHV-UHFFFAOYSA-N bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- AUAHHJJRFHRVPV-BZDVOYDHSA-N ethambutol dihydrochloride Chemical compound [Cl-].[Cl-].CC[C@@H](CO)[NH2+]CC[NH2+][C@@H](CC)CO AUAHHJJRFHRVPV-BZDVOYDHSA-N 0.000 description 1
- 229960001618 ethambutol hydrochloride Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000009474 immediate action Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003509 long acting drug Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP23452182A JPS59122425A (ja) | 1982-12-27 | 1982-12-27 | 持続性製剤およびその製造法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP23452182A JPS59122425A (ja) | 1982-12-27 | 1982-12-27 | 持続性製剤およびその製造法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS59122425A JPS59122425A (ja) | 1984-07-14 |
JPH0460090B2 true JPH0460090B2 (da) | 1992-09-25 |
Family
ID=16972323
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP23452182A Granted JPS59122425A (ja) | 1982-12-27 | 1982-12-27 | 持続性製剤およびその製造法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS59122425A (da) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3437599A1 (de) * | 1984-10-13 | 1986-04-17 | Dolorgiet GmbH & Co KG, 5205 St Augustin | Ibuprofen enthaltende weichgelatinekapseln und verfahren zu ihrer herstellung |
GB8524421D0 (en) * | 1985-10-03 | 1985-11-06 | Boots Co Plc | Therapeutic agents |
CH669523A5 (da) * | 1986-06-25 | 1989-03-31 | Mepha Ag | |
PT956858E (pt) * | 1998-04-30 | 2002-04-29 | Renata Maria Anna Caval Vesely | Composicoes farmaceuticas contendo lactobacilos para o tratamento de infeccoes vaginais |
EP1551372B8 (en) | 2002-09-20 | 2018-08-01 | Alpharma Pharmaceuticals LLC | Sequestering subunit and related compositions and methods |
FR2848855B1 (fr) * | 2002-12-23 | 2005-02-11 | Aventis Pharma Sa | Compositions pour administration orale de principes actifs necessitant un masquage du gout |
-
1982
- 1982-12-27 JP JP23452182A patent/JPS59122425A/ja active Granted
Non-Patent Citations (2)
Title |
---|
JOURNAL OF PHARMACEUTICAL SCIENCES=1966 * |
JOURNAL OF PHARMACEUTICAL SCIENCES=1968 * |
Also Published As
Publication number | Publication date |
---|---|
JPS59122425A (ja) | 1984-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2893191B2 (ja) | 放出制御性マトリックス剤 | |
EP0368247B1 (en) | Controlled release preparations | |
KR100203339B1 (ko) | 의약용 방출조절 매트릭스 | |
EP0324981B1 (en) | New galenic formulations with programmed release | |
US3400197A (en) | Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules | |
KR100712356B1 (ko) | 서방성 제제 및 그의 제조방법 | |
US5186943A (en) | Compressed-molded preparations | |
JPS6327424A (ja) | 徐放性製剤およびその製造法 | |
DK162697B (da) | Tabletter til langsom, nulte-ordens frigivelse via styret overfladeerosion | |
US4786495A (en) | Therapeutic agents | |
NO313124B1 (no) | Anvendelse av tramadol i fremstillingen av et medikament for behandling av smerte | |
MXPA01012889A (es) | Composiciones farmaceuticas orales de liberacion controlada y sabor disfrazado. | |
JP2004518709A5 (da) | ||
MX2007012124A (es) | Formulaciones mejoradas de fenofibrato. | |
JP5881700B2 (ja) | ブロナンセリン経口放出制御型医薬組成物 | |
JP2002517431A (ja) | マイクロ浸透圧制御薬物送達システム | |
JPH0460090B2 (da) | ||
HRP20010650A2 (en) | Controlled-release compositions of betahistine | |
JP2892858B2 (ja) | 放出制御製剤およびその製造法 | |
US5726201A (en) | Gemfibrozil containing pharmaceutical compositions | |
JPH0530810B2 (da) | ||
NO160902B (no) | Fremgangsm te for ekstrahering av en vaeske. | |
JPH04321621A (ja) | 徐放性細粒剤およびその製法 | |
JPH04273816A (ja) | パルス放出型有核錠 | |
JP2760012B2 (ja) | 持続性細粒剤 |